Optimized rat models better mimic patients with irinotecan-induced severe diarrhea

References

• Al Shoyaib A, Archie SR, Karamyan VT. 2019. Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res. 37(1):12. doi: 10.1007/s11095-019-2745-x.
   PubMed Web of Science ®Google Scholar
• Bailly C. 2019. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 148:104398. doi: 10.1016/j.phrs.2019.104398.
   PubMed Web of Science ®Google Scholar
• Basu S, Zeng M, Yin T, Gao S, Hu M. 2016. Development and validation of an UPLC–MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 1015–1016:34–41. doi: 10.1016/j.jchromb.2016.02.012.
   PubMed Web of Science ®Google Scholar
• Bateman E, Weaver E, Klein G, Wignall A, Wozniak B, Plews E, Mayo B, White I, Keefe D. 2016. Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis. Support Care Cancer. 24(1):377–385. doi: 10.1007/s00520-015-2806-6.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Salamone SJ. 2012. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J Clin Oncol. 30(31):3896–3897. doi: 10.1200/JCO.2012.44.2863.
   PubMed Web of Science ®Google Scholar
• Bleich EM, Martin M, Bleich A, Klos A. 2010. The Mongolian gerbil as a model for inflammatory bowel disease. Int J Exp Pathol. 91(3):281–287. doi: 10.1111/j.1365-2613.2009.00701.x.
   PubMed Web of Science ®Google Scholar
• Dahlgren D, Rosenqvist E, Hellström PM, Nygren P, Kullenberg F, Peters K, Sjöblom M, Lennernäs H. 2022. Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats. Basic Clin Pharmacol Toxicol. 131(6):536–546. doi: 10.1111/bcpt.13790.
   PubMed Web of Science ®Google Scholar
• Deng C, Deng B, Jia L, Tan H, Zhang P, Liu S, Zhang Y, Song A, Pan L. 2017. Preventive effects of a Chinese herbal formula, Shengjiang Xiexin decoction, on irinotecan-induced delayed-onset diarrhea in rats. Evid Based Complement Alternat Med. 2017:7350251. doi: 10.1155/2017/7350251.
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM. 2007. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy. 53(5):360–369. doi: 10.1159/000107458.
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. 2003. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol. 18(9):1095–1100. doi: 10.1046/j.1440-1746.2003.03136.x.
   PubMed Web of Science ®Google Scholar
• Gnutzmann DM, Mechel J, Schmitz A, Köhler K, Krone D, Bellemann N, Gockner TL, Mokry T, Kortes N, Sommer C-M, et al. 2015. Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model. J Vasc Interv Radiol. 26(5):746–754. doi: 10.1016/j.jvir.2014.12.016.
   PubMed Web of Science ®Google Scholar
• Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. 1998. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol. 42(2):165–170. doi: 10.1007/s002800050801.
   PubMed Web of Science ®Google Scholar
• Irving AA, Yoshimi K, Hart ML, Parker T, Clipson L, Ford MR, Kuramoto T, Dove WF, Amos-Landgraf JM. 2014. The utility of Apc-mutant rats in modeling human colon cancer. Dis Model Mech. 7(11):1215–1225. doi: 10.1242/dmm.016980.
   PubMed Web of Science ®Google Scholar
• Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H, Sato K. 1993. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol. 45(5):444–448. doi: 10.1111/j.2042-7158.1993.tb05573.x.
   PubMed Web of Science ®Google Scholar
• Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T. 2000. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 46(3):211–220. doi: 10.1007/s002800000151.
   PubMed Web of Science ®Google Scholar
• Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, Uchida K, Onoue M, Yokokura T. 2011. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol. 67(1):201–213. doi: 10.1007/s00280-010-1310-4.
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. 2008. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 62(1):33–41. doi: 10.1007/s00280-007-0570-0.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. 2010. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
   Google Scholar
• Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, Kato I, Yokokura T. 2008. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 61(4):595–605. doi: 10.1007/s00280-007-0512-x.
   PubMed Web of Science ®Google Scholar
• Pharma S. 2010. Safety data sheet irinotecan hydrochloride injection. http://www.gopharm.si/varnostni_listi/zdravila/Irinotecan%20Hydrochloride%20Injection.pdf.
   Google Scholar
• Sezer A, Usta U, Cicin I. 2009. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol. 26(3):350–357. doi: 10.1007/s12032-008-9128-1.
   PubMed Web of Science ®Google Scholar
• Sgaragli GP, Valoti M, Fusi F, Palmi M, Mantovani P, De Santi MM, Lorenzini L, Tosi P. 1993. Toxic injury to rat gut musculature following intraperitoneal administration of 2-t-butyl-4-methoxyphenol. Eur J Pharmacol. 248(2):121–129. doi: 10.1016/0926-6917(93)90033-m.
   PubMed Web of Science ®Google Scholar
• Stein A, Voigt W, Jordan K. 2010. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2(1):51–63. doi: 10.1177/1758834009355164.
   PubMedGoogle Scholar
• Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N, Keefe DM. 2009. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol. 90(5):489–499. doi: 10.1111/j.1365-2613.2009.00671.x.
   PubMed Web of Science ®Google Scholar
• Stringer AM, Richard RJG, Logan M, Bowen JM, Yeoh AS-J, Burns J, Keefe DMK. 2007. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med. 232(1):96–106. doi: 10.3181/00379727-207-2320096.
   PubMed Web of Science ®Google Scholar
• Sun R, Zhu L, Li L, Song W, Gong X, Qi X, Wang Y, Ghose R, Gao S, Hu M, et al. 2020. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: critical role of gut Ugt. Toxicol Appl Pharmacol. 398:115032. doi: 10.1016/j.taap.2020.115032.
   PubMed Web of Science ®Google Scholar
• Swami U, Goel S, Mani S. 2013. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets. 14(7):777–797. doi: 10.2174/1389450111314070007.
   PubMed Web of Science ®Google Scholar
• Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, Smith PC. 2007. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther. 320(1):29–37. doi: 10.1124/jpet.106.110924.
   PubMed Web of Science ®Google Scholar
• Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL. 2002. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62(20):5778–5784.
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, et al. 2014. Irinophore C, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Invest New Drugs. 32(6):1071–1082. doi: 10.1007/s10637-014-0138-x.
   PubMed Web of Science ®Google Scholar
• Yang C-F, Yu-Chih Chen M, Chen T-I, Cheng C-F. 2014. Dose-dependent effects of isoflurane on cardiovascular function in rats. Tzu Chi Med J. 26(3):119–122. doi: 10.1016/j.tcmj.2014.07.005.
   Google Scholar
• Yim SK, Kim SW, Lee ST. 2021. Efficient stool collection methods for evaluating the diarrhea score in mouse diarrhea models. In Vivo. 35(4):2115–2125. doi: 10.21873/invivo.12481.
   PubMed Web of Science ®Google Scholar